



QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC TEST REPORT

New co directo	layan Medical Drugs	laitumkhrah	n, Office of the mission	REPORT NO ISSUE DAT CUSTOMEI DATE PAGE NO	E : R REFERENCE : :	EFRAC/2023/DRG/RG/0 23/11/2023 TRF 17/11/2023 1 of 3	3656
			SAN	IPLE DETAILS			
SAMP	LE REGISTRATION	DETAILS					
	e Name		1etformin 500mg	Sample Sample Batch S		e : 20/11/2023	
Registr	e Receipt Date ration No of Manufacturer No.	: N/A	/2023 C/2023/DRG/RG/03656 SL QC-0015	Date of	Expiry	: Sep-2025	
	f Mfg. LE ANALYSIS DETA is Starting Date		1/2023	5	s Completion Date	e : 23/11/202	3
				EST RESULT		1	1
SL No.	TEST PARAMETER		TESTING / REF. PROCEDURE	LABEL CLAIM	UOM	ACCEPTANCE LIMIT	RESULTS
1	Description		Indian Pharmacopoeia 2022	-	_	White colour biconvex caplet shaped uncoated tablet having breakline in one side and plain on other side.	White colour biconvex caplet shaped uncoated tablet having breakline in one side and plain on other side.
2	Identification A		Indian Pharmacopoeia 2022	-	_	The IR spectrum obtained with the sample should concordant with the reference spectrum of metformin HCL	The IR spectrum obtained with the sampleis concordant with the reference spectrum of metformin HCL









QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC TEST REPORT

New co directo	D TO : alayan Medical Drugs And Ser olony shillong, DHS, laitumkh pr,NHM, Shillong, East Khasi H 9CENCE No :	rah, Office of the mission	REPORT N ISSUE DA ⁻ CUSTOME DATE PAGE NO	TE : ER REFERENCE : :	EFRAC/2023/DRG/RG/0 23/11/2023 TRF 17/11/2023 2 of 3	3656
	-	Ţ	EST RESULT			
SL No.	TEST PARAMETER	TESTING / REF. PROCEDURE	LABEL CLAIM	иом	ACCEPTANCE LIMIT	RESULTS
3	Identification B	Indian Pharmacopoeia 2022	-	C C	An orange-red colour should produced which darkens on keeping	An orange-red colour produced which darkens on keeping
4	Identification C	Indian Pharmacopoeia 2022	0	· · · · · · · · · · · · · · · · · · ·	A curdy white ppt should formed which should not soluble in HNO3 but soluble in dilute ammonia solution.	A curdy white pptis formed which insoluble in HNO3 but soluble in dilute ammonia solution.
5	Uniformity of weight	Indian Pharmacopoeia 2022	-	%	(±)5.0	Avg wt : 751.67 mg , (-) Dev : 1.03 , (+) Dev : 2.02
6	Disintigration	Indian Pharmacopoeia 2022	-	Min./Sec.	NMT 15 Minutes	Min : 02 Min 25 Sec , Max : 03 Min 12 Sec
7	Dissolution	Indian Pharmacopoeia 2022	500 mg/Tab	% of L.C.	NLT 75.0	Avg : 89.11 , Max : 90.54 , Min : 88.19
8	Assay	Indian Pharmacopoeia 2022	500 mg/Tab	% of L.C.	475.0 - 525.0 mg/Tab i.e. 95.0 - 105.0	486.75 mg/Tab i.e. 97.34
9	Related Substances	Indian Pharmacopoeia 2022	-	%	Dicyandiamide impurity : NMT 0.02 ,Any other impurities : NMT 0.1	Dicyandiamide impurity :0.0029, Any other impurities : Not detected

In the opinion of the undersigned, the Sample referred to above <u>is of Standard Quality</u> / <u>is not of Standard Quality</u> as defined in the Act or the Rules madethere under for the reasons given below:









QA.15.0.0.3

FORM 39 [RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC TEST REPORT

ISSUED TO : Meghalayan Medical Drugs And Services Limited	REPORT NO ISSUE DATE	: EFRAC/2023/DRG/RG/03656 : 23/11/2023
New colony shillong, DHS, laitumkhrah, Office of the mission director,NHM, Shillong, East Khasi Hills Meghalaya, 793003 shillong 793003 MFG. LICENCE NO :	CUSTOMER REFERENCE DATE PAGE NO	: TRF : 17/11/2023 : 3 of 3

UOM : Unit of Measurement

:

REMARKS : The sample is tested as per test procedure shared by client and Opinion on Quality is drawn against the results obtained for tested parameters only.

FLECTK

Note

-END OF THE TEST REPORT-



